Follow us on:

Open Orphan world’s first COVID-19 characterisation study (Interview)

Open Orphan plc (LON:ORPH) Executive Chairman Cathal Friel joins DirectorsTalk Interviews to discuss results from the world’s first COVID-19 characterisation study.

Cathal explains what these results mean for Open Orphan, plans to initiate the next phase of the Human Challenge Programme, studies to approve new vaccines and antivirals and with 95% of 2022 targeted revenues contracted being non-Covid revenue can we expect some COVID-19 revenue this year.

Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials.

Find more news, interviews, share price & company profile here for:hVIVO plc
Open Orphan plc

Share this interview

Other Interviews

Open Orphan dual business firing on all four cylinders (Interview) October 5, 2020
Open Orphan Land Major Deal – Chairman Cathal Friel says more to come (Interview) May 5, 2020
Open Orphan ‘Expect some quite substantial contracts’ says Cathal Friel (Interview) April 24, 2020
Open Orphan Coronavirus and RSV human challenge studies underway (Interviews) March 10, 2020
Open Orphan Investor Presentation Feb 2020 February 18, 2020

More News

Open Orphan name change to hVIVO plc now effective October 25, 2022
Open Orphan to hold a Capital Markets Day on 2 November 2022 October 20, 2022
Open Orphan appoints Stephen Pinkerton as CFO October 18, 2022
Open Orphan further positive data for FLU-v September 30, 2022
Open Orphan CEO Yamin ‘Mo’ Khan purchases shares in the company September 29, 2022
Open Orphan three upcoming scientific presentations September 27, 2022
Open Orphan to change name to hVIVO plc September 8, 2022
Open Orphan continued its profitable momentum into 2022 September 8, 2022
Open Orphan clinical laboratories awarded high standard of excellence by CAP September 1, 2022
Open Orphan to release its interim results on 8 September 2022 August 25, 2022

Search

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.